Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hemogenyx (HEMO) Share Price

Price 150.00p on 27-06-2025 at 18:50:06
Change -1.00p -0.65%
Buy 156.50p
Sell 150.00p
Buy / Sell HEMO Shares
Last Trade: Sell 151.00 at 150.25p
Day's Volume: 102,667
Last Close: 153.25p
Open: 150.00p
ISIN: GB00BQVXM815
Day's Range 150.00p - 150.00p
52wk Range: 0.876p - 420.00p
Market Capitalisation: £7m
VWAP: 159.44397p
Shares in Issue: 5m

Hemogenyx (HEMO) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 151 150.25p Ordinary
16:28:12 - 27-Jun-25
Sell* 1,000 150.3282p Ordinary
16:19:21 - 27-Jun-25
Sell* 2 150.00p SI Trade
15:48:20 - 27-Jun-25
Buy* 25 156.50p SI Trade
15:48:20 - 27-Jun-25
Buy* 6,423 154.84p Ordinary
15:48:15 - 27-Jun-25
Buy* 323 152.90p Ordinary
15:28:08 - 27-Jun-25
Sell* 507 149.702p Ordinary
15:19:22 - 27-Jun-25
Sell* 671 149.704p Ordinary
15:14:31 - 27-Jun-25
Sell* 98 149.70p Ordinary
14:55:28 - 27-Jun-25
Buy* 800 152.90p Ordinary
14:36:09 - 27-Jun-25
See more Hemogenyx trades

Hemogenyx (HEMO) Share Price History

Time period:
to
Date Open High Low Close Volume
27th Jun 2025 (Fri) 150.00 150.00 150.00 153.25 102,667
26th Jun 2025 (Thu) 152.25 154.25 152.25 154.25 37,398
25th Jun 2025 (Wed) 165.00 165.00 154.00 152.25 64,829
24th Jun 2025 (Tue) 168.50 168.50 168.50 169.25 8,271
23rd Jun 2025 (Mon) 177.50 177.50 177.50 169.75 21,123
20th Jun 2025 (Fri) 170.00 170.00 170.00 172.25 4,852
19th Jun 2025 (Thu) 173.75 175.00 173.75 175.00 3,151
18th Jun 2025 (Wed) 170.50 170.50 170.00 173.75 24,386
17th Jun 2025 (Tue) 175.00 175.00 175.00 172.25 12,535
16th Jun 2025 (Mon) 175.00 175.00 173.00 172.25 27,013
13th Jun 2025 (Fri) 177.25 177.50 177.25 177.50 1,612
12th Jun 2025 (Thu) 175.50 175.50 175.50 177.25 1,837
11th Jun 2025 (Wed) 177.50 177.50 175.50 175.50 2,553
10th Jun 2025 (Tue) 177.50 177.50 177.50 177.50 2,497
9th Jun 2025 (Mon) 177.25 177.50 177.25 177.50 740
6th Jun 2025 (Fri) 177.25 177.25 177.25 177.25 13,046
5th Jun 2025 (Thu) 175.00 175.00 175.00 177.25 5,000
4th Jun 2025 (Wed) 179.50 179.50 179.50 177.25 22,959
3rd Jun 2025 (Tue) 175.50 180.00 175.50 178.50 302,143
2nd Jun 2025 (Mon) 175.00 175.00 173.00 174.75 23,056
30th May 2025 (Fri) 176.25 176.25 176.25 176.25 4,545
29th May 2025 (Thu) 177.50 177.50 176.25 176.25 13,205
See more Hemogenyx price history

Hemogenyx (HEMO) Regulatory News

Date Source Headline
17th Jun 2025 7:00 am RNS Clearance to Proceed with Pediatric Expansion
3rd Jun 2025 2:02 pm RNS Placing to Raise £451,250 and Director’s Dealing
3rd Jun 2025 7:00 am RNS Second Patient Passes Initial Safety Tests
30th May 2025 3:14 pm RNS Total Voting Rights
29th May 2025 2:06 pm RNS Result of AGM
14th May 2025 7:00 am RNS-R Pediatric Amendment to Clinical Protocol
13th May 2025 7:00 am RNS AGM Correction
8th May 2025 7:00 am RNS Placing to Raise £451,250 and Director’s Dealing
2nd May 2025 4:24 pm RNS Notice of AGM
2nd May 2025 7:00 am RNS Second Patient Treated with HG-CT-1 CAR-T Therapy
See more Hemogenyx regulatory news

Hemogenyx (HEMO) Share News

TRADING UPDATES: Safestay mulls asset sale; Sound Energy inks 2 deals

17th Jun 2025 15:48

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

TRADING UPDATES: Valereum invests in Blubird; Hemogenyx raises funds

3rd Jun 2025 22:11

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

UK shareholder meetings calendar - next 7 days

22nd May 2025 14:05

Read More

IN BRIEF: Hemogenyx expands trial to include paediatric patients

14th May 2025 14:28

Hemogenyx Pharmaceuticals PLC - London-headquartered biopharmaceutical company focused on treatments for blood diseases - Says it has filed, with the US Food & Drug Administration, an amendment to the clinical protocol for its ongoing phase 1 clinical trial of HG-CT-1 to include paediatric patients with relapsed/refractory acute myeloid leukemia, or R/R AML. CAR-T therapy HG-CT-1 is currently undergoing clinical trials to treat R/R AML in adults. Company says the amendment "seeks to expand eligibility for the trial beyond adult patients to include children and adolescents with R/R AML, an aggressive disease with limited treatment options and poor prognosis in the relapsed/refractory setting". Adds that expanding eligibility reflects its commitment to broadening the potential impact of HG-CT-1, and to addressing a critical unmet medical need in paediatric oncology. Read More

TRADING UPDATES: GlobalData suspends buyback; Hemogenyx trial progress

2nd May 2025 22:05

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More

See more Hemogenyx news
FTSE 100 Latest
Value8,798.91
Change63.31

Login to your account

Forgot Password?

Not Registered